A trial to assess the 2-year retention rate of golimumab for arthritis, psoriatic arthritis and ankylosing spondylitis patients from a multicentre, observational cohort (the LORHEN registry).
Phase of Trial: Phase IV
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 26 Aug 2016 New trial record